Transmembrane Domains 4 and 7 of the M1Muscarinic Acetylcholine Receptor Are Critical for Ligand Binding and the Receptor Activation Switch*

Activation of the muscarinic acetylcholine receptors requires agonist binding followed by a conformational change, but the ligand binding and conformation-switching residues have not been completely identified. Systematic alanine-scanning mutagenesis has been used to assess residues 142–164 in transmembrane helix 4 and 402–421 in transmembrane helix 7 of the M1muscarinic acetylcholine receptor. Several inward-facing amino acid side chains in the exofacial parts of transmembrane helices 4 and 7 contribute to acetylcholine binding. Alanine substitution of the aromatic residues in this group reduced signaling efficacy, suggesting that they may form part of a charge-stabilized aromatic cage, which triggers rotation and movement of the transmembrane helices. The mutation of adjacent residues modulated receptor activation, either reducing signaling or causing constitutive activation. In the buried endofacial section of transmembrane helix 7, alanine substitution mutants of the conserved NSXXNPXXY motif displayed strongly reduced signaling efficacy, despite having increased or unchanged acetylcholine affinity. These residues may have dual functions, forming intramolecular contacts that stabilize the receptor in the inactive ground state, but that are broken, allowing them to form new intramolecular bonds in the activated state. This conformational rearrangement is critical to produce a G protein binding site and may represent a key mechanism of receptor activation.

[1]  J. Wess,et al.  Functional role of proline and tryptophan residues highly conserved among G protein‐coupled receptors studied by mutational analysis of the m3 muscarinic receptor. , 1993, The EMBO journal.

[2]  K D Ridge,et al.  Light-induced exposure of the cytoplasmic end of transmembrane helix seven in rhodopsin. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  E. Hulme,et al.  A Network of Conserved Intramolecular Contacts Defines the Off-state of the Transmembrane Switch Mechanism in a Seven-transmembrane Receptor* , 2000, The Journal of Biological Chemistry.

[4]  S. Trumpp-Kallmeyer,et al.  This is not a G protein-coupled receptor. , 1993, Trends in pharmacological sciences.

[5]  E. Hulme,et al.  The function of a highly-conserved arginine residue in activation of the muscarinic M1 receptor. , 1995, European journal of pharmacology.

[6]  E C Hulme,et al.  The Functional Topography of Transmembrane Domain 3 of the M1 Muscarinic Acetylcholine Receptor, Revealed by Scanning Mutagenesis* , 1999, The Journal of Biological Chemistry.

[7]  M. Sabio,et al.  Recognition of cholinergic agonists by the muscarinic receptor. 1. Acetylcholine and other agonists with the NCCOCC backbone. , 1983, Journal of medicinal chemistry.

[8]  J L Sussman,et al.  Protein Data Bank (PDB): database of three-dimensional structural information of biological macromolecules. , 1998, Acta crystallographica. Section D, Biological crystallography.

[9]  M. Brann,et al.  Identification of a Ligand-dependent Switch within a Muscarinic Receptor* , 1998, The Journal of Biological Chemistry.

[10]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[11]  Elaine C. Meng,et al.  An Activation Switch in the Ligand Binding Pocket of the C5a Receptor* , 2001, The Journal of Biological Chemistry.

[12]  M. Zuscik,et al.  Novel Aromatic Residues in Transmembrane Domains IV and V Involved in Agonist Binding at α1a-Adrenergic Receptors* , 2000, The Journal of Biological Chemistry.

[13]  D. Oprian,et al.  Constitutively active mutants of rhodopsin , 1992, Neuron.

[14]  T. Schwartz,et al.  Conversion of agonist site to metal-ion chelator site in the beta(2)-adrenergic receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Sealfon,et al.  Conserved helix 7 tyrosine functions as an activation relay in the serotonin 5HT(2C) receptor. , 2000, Brain research. Molecular brain research.

[16]  C. Guenet,et al.  Site-directed mutagenesis of the putative human muscarinic M2 receptor binding site. , 1999, European journal of pharmacology.

[17]  K. Page,et al.  Scanning mutagenesis identifies amino acid side chains in transmembrane domain 5 of the M(1) muscarinic receptor that participate in binding the acetyl methyl group of acetylcholine. , 2000, Molecular pharmacology.

[18]  K. Konvička,et al.  A proposed structure for transmembrane segment 7 of G protein-coupled receptors incorporating an asn-Pro/Asp-Pro motif. , 1998, Biophysical journal.

[19]  E. Hulme,et al.  The role of the aspartate-arginine-tyrosine triad in the m1 muscarinic receptor: mutations of aspartate 122 and tyrosine 124 decrease receptor expression but do not abolish signaling. , 1997, Molecular pharmacology.

[20]  R. Barlow Introduction to Chemical Pharmacology , 1964 .

[21]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[22]  C. Fraser,et al.  Site-directed mutagenesis of the rat m1 muscarinic acetylcholine receptor. Role of conserved cysteines in receptor function. , 1992, The Journal of biological chemistry.

[23]  S. Lazareno,et al.  Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis. , 1995, Molecular pharmacology.

[24]  J. Wess,et al.  Role of conserved threonine and tyrosine residues in acetylcholine binding and muscarinic receptor activation. A study with m3 muscarinic receptor point mutants. , 1992, The Journal of biological chemistry.

[25]  J. Anderson,et al.  A mutation in the hamster alpha1B-adrenergic receptor that differentiates two steps in the pathway of receptor internalization. , 1997, Molecular pharmacology.

[26]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[27]  Marvin C. Gershengorn,et al.  Interactions between Conserved Residues in Transmembrane Helices 1, 2, and 7 of the Thyrotropin-releasing Hormone Receptor* , 1997, The Journal of Biological Chemistry.

[28]  J. Jakubík,et al.  Evidence for a Tandem Two-site Model of Ligand Binding to Muscarinic Acetylcholine Receptors* , 2000, The Journal of Biological Chemistry.

[29]  Gebhard F. X. Schertler,et al.  Arrangement of rhodopsin transmembrane α-helices , 1997, Nature.

[30]  E. Hulme,et al.  Alanine-scanning mutagenesis of transmembrane domain 6 of the M(1) muscarinic acetylcholine receptor suggests that Tyr381 plays key roles in receptor function. , 1999, Molecular pharmacology.

[31]  T. Schwartz,et al.  Partial agonism through a zinc-Ion switch constructed between transmembrane domains III and VII in the tachykinin NK(1) receptor. , 2000, Molecular pharmacology.

[32]  K Konvicka,et al.  A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor. , 1994, Molecular pharmacology.

[33]  H. Khorana,et al.  Requirement of Rigid-Body Motion of Transmembrane Helices for Light Activation of Rhodopsin , 1996, Science.

[34]  L. Audoly,et al.  Substitution of charged amino acid residues in transmembrane regions 6 and 7 affect ligand binding and signal transduction of the prostaglandin EP3 receptor. , 1997, Molecular pharmacology.

[35]  K. Nakanishi,et al.  Movement of retinal along the visual transduction path. , 2000, Science.

[36]  E. Hulme,et al.  The conformational switch in 7-transmembrane receptors: the muscarinic receptor paradigm. , 1999, European journal of pharmacology.

[37]  E. Hulme,et al.  Scanning mutagenesis of transmembrane domain 3 of the m1 muscarinic acetylcholine receptor , 1998, Journal of Physiology-Paris.

[38]  S. Karnik,et al.  Role of Transmembrane Helix IV in G-protein Specificity of the Angiotensin II Type 1 Receptor* , 1999, The Journal of Biological Chemistry.